Guggenheim Starts Coverage on Sagimet Biosciences with Buy Rating
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
/ 2 items
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.